8-K: Current report filing
Published on April 24, 2008
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 |
|
FORM 8-K
|
|
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
Date of
Report (Date of earliest event reported): April 9, 2008
|
|
ACCESS PHARMACEUTICALS,
INC.
|
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
0-9314
|
83-0221517
|
|
|
|
|
|
(State
or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
|
2600 Stemmons Freeway, Suite
176
Dallas, Texas |
|
75207
|
|
|
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number, including
area code:
|
(214) 905-5100
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report)
|
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
|
/ /
|
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
|
|
/ /
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
/ /
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
/ /
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
1.01 ENTRY INTO A MATERIAL DEFINITIVE
AGREEMENT
On April 9, 2008, Mr. Davis, Chief Executive Officer of Access
Pharmaceuticals, Inc, and the Company amended Mr. Davis' Employment
Agreement with the Company. Pursuant to the terms of the amendment and effective
April 1, 2008, Mr. Davis will be paid an annual salary of $240,000. In addition,
Mr Davis agreed to forgo any stock options awarded under the terms of the
original employment agreement.
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ACCESS PHARMACEUTICALS, INC.
(Registrant)
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
|
|
|
|
|
Stephen B. Thompson
|
|
|
|
Vice President, Chief Financial
Officer
|
|
Date: April 24, 2008
|
|